Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis - Top-Institutions - MDSpire

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

  • By

  • Luz M Toribio

  • Carolina Guzman

  • Alessandra Vasquez

  • Herbert Saavedra

  • Isidro Gonzales

  • Javier A Bustos

  • Hector H García

  • for the Cysticercosis Working Group in Peru

  • January 20, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Neurology
    • Tropical Medicine

  • #2

    Universidad Peruana Cayetano Heredia
    Universidad Peruana Cayetano Heredia

    Lima, Lima

    Key Differentiators

    • Infectious Diseases
    • Parasitology
    • Neurology

  • #3

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Parasitology
    • Public Health

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Infectious Diseases
    • Global Health

Original Source(s)

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

  • by Luz M Toribio, Carolina Guzman, Alessandra Vasquez, Herbert Saavedra, Isidro Gonzales, Javier A Bustos, Hector H García, for the Cysticercosis Working Group in Peru

  • January 20, 2026

Related Content

ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR

Magnetic resonance enterography to predict subsequent disabling Crohn’s disease in newly diagnosed patients (METRIC-EF)—multivariable prediction model, multicentre diagnostic inception cohort

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.